This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent. Top assignee: Merck Sharp & Dohme LLC. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: David N Hunter: Innovator in Selective Cytotoxic Agents
Introduction
David N Hunter is a notable inventor based in Hatfield, PA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of selective cytotoxic agents. With a total of 2 patents, his work focuses on innovative solutions for treating HIV and related conditions.
Latest Patents
Hunter's latest patents include the development of tetrahydroquinazoline derivatives as selective cytotoxic agents. These derivatives are designed to selectively kill HIV-infected GAG-POL expressing cells without causing cytotoxicity to HIV-naïve cells. This innovation holds promise for the treatment or prophylaxis of HIV infection, as well as for delaying the onset or progression of AIDS or AIDS Related Complex (ARC).
Career Highlights
David N Hunter is currently associated with Merck Sharp & Dohme LLC, where he continues to advance his research in the pharmaceutical industry. His work is characterized by a commitment to developing effective treatments for serious health conditions.
Collaborations
Some of his notable coworkers include Abdellatif El Marrouni and Yunlong Zhang, who contribute to the collaborative efforts in his research endeavors.
Conclusion
David N Hunter's innovative work in the field of selective cytotoxic agents showcases his dedication to improving health outcomes for individuals affected by HIV. His contributions are paving the way for new therapeutic approaches in the fight against this virus.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile